1. Home
  2. QLGN vs CISS Comparison

QLGN vs CISS Comparison

Compare QLGN & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • CISS
  • Stock Information
  • Founded
  • QLGN 1996
  • CISS 2022
  • Country
  • QLGN United States
  • CISS Greece
  • Employees
  • QLGN N/A
  • CISS N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • CISS Marine Transportation
  • Sector
  • QLGN Health Care
  • CISS Consumer Discretionary
  • Exchange
  • QLGN Nasdaq
  • CISS Nasdaq
  • Market Cap
  • QLGN 2.8M
  • CISS 2.8M
  • IPO Year
  • QLGN N/A
  • CISS N/A
  • Fundamental
  • Price
  • QLGN $3.54
  • CISS $3.30
  • Analyst Decision
  • QLGN
  • CISS
  • Analyst Count
  • QLGN 0
  • CISS 0
  • Target Price
  • QLGN N/A
  • CISS N/A
  • AVG Volume (30 Days)
  • QLGN 9.1K
  • CISS 121.3K
  • Earning Date
  • QLGN 08-13-2025
  • CISS 08-21-2025
  • Dividend Yield
  • QLGN N/A
  • CISS N/A
  • EPS Growth
  • QLGN N/A
  • CISS N/A
  • EPS
  • QLGN N/A
  • CISS N/A
  • Revenue
  • QLGN N/A
  • CISS $38,174,754.00
  • Revenue This Year
  • QLGN N/A
  • CISS N/A
  • Revenue Next Year
  • QLGN N/A
  • CISS N/A
  • P/E Ratio
  • QLGN N/A
  • CISS N/A
  • Revenue Growth
  • QLGN N/A
  • CISS N/A
  • 52 Week Low
  • QLGN $2.85
  • CISS $2.85
  • 52 Week High
  • QLGN $29.44
  • CISS $23.25
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 44.87
  • CISS 41.14
  • Support Level
  • QLGN $3.37
  • CISS $3.20
  • Resistance Level
  • QLGN $3.85
  • CISS $4.00
  • Average True Range (ATR)
  • QLGN 0.23
  • CISS 0.37
  • MACD
  • QLGN -0.03
  • CISS -0.03
  • Stochastic Oscillator
  • QLGN 34.29
  • CISS 8.33

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.

Share on Social Networks: